Capstone Triton Financial Group LLC Sells 588 Shares of Moderna, Inc. (NASDAQ:MRNA)

Capstone Triton Financial Group LLC lowered its position in Moderna, Inc. (NASDAQ:MRNA) by 18.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,683 shares of the company’s stock after selling 588 shares during the period. Capstone Triton Financial Group LLC’s holdings in Moderna were worth $319,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Ashton Thomas Private Wealth LLC purchased a new stake in Moderna in the second quarter worth $26,000. Family Firm Inc. purchased a new position in Moderna during the second quarter valued at $33,000. Cedar Wealth Management LLC boosted its holdings in shares of Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after buying an additional 90 shares in the last quarter. Westside Investment Management Inc. purchased a new stake in shares of Moderna in the 1st quarter worth about $32,000. Finally, Bank & Trust Co bought a new position in shares of Moderna in the 2nd quarter worth about $36,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on MRNA shares. Royal Bank of Canada reissued a “sector perform” rating and set a $75.00 price objective on shares of Moderna in a research note on Thursday. JPMorgan Chase & Co. cut Moderna from a “neutral” rating to an “underweight” rating and dropped their price target for the stock from $88.00 to $70.00 in a research report on Friday, September 13th. Evercore ISI restated an “in-line” rating and issued a $120.00 price target on shares of Moderna in a research note on Thursday, June 27th. HSBC upgraded Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price objective for the company in a research note on Wednesday, August 28th. Finally, Barclays cut their target price on Moderna from $155.00 to $125.00 and set an “overweight” rating on the stock in a research note on Monday, September 16th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Moderna presently has a consensus rating of “Hold” and an average price target of $100.44.

Moderna Price Performance

MRNA opened at $65.69 on Friday. The company’s 50-day simple moving average is $90.07 and its two-hundred day simple moving average is $110.76. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $170.47. The stock has a market capitalization of $25.18 billion, a P/E ratio of -4.19 and a beta of 1.68. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The company had revenue of $241.00 million for the quarter, compared to the consensus estimate of $128.41 million. During the same quarter in the prior year, the firm earned ($3.62) earnings per share. The firm’s revenue for the quarter was down 29.9% compared to the same quarter last year. As a group, analysts predict that Moderna, Inc. will post -9.52 EPS for the current year.

Insider Activity

In related news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the sale, the chief financial officer now owns 8,600 shares of the company’s stock, valued at $682,754. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CFO James M. Mock sold 1,321 shares of the stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares in the company, valued at approximately $682,754. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO James M. Mock sold 689 shares of the business’s stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $118.24, for a total transaction of $81,467.36. Following the sale, the chief financial officer now owns 7,269 shares of the company’s stock, valued at $859,486.56. The disclosure for this sale can be found here. Insiders have sold 93,158 shares of company stock valued at $11,167,312 in the last ninety days. 15.70% of the stock is currently owned by company insiders.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.